

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> :  C12Q 1/68, C12N 15/00 G01N 33/574		A2	(11) International Publication Number: <b>WO 87/07646</b>  (43) International Publication Date: 17 December 1987 (17.12.87)																																																																								
<p>(21) International Application Number: <b>PCT/US87/01282</b></p> <p>(22) International Filing Date: 3 June 1987 (03.06.87)</p> <p>(31) Priority Application Number: 871,102</p> <p>(32) Priority Date: 4 June 1986 (04.06.86)</p> <p>(33) Priority Country: US</p> <p>(71) Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US).</p> <p>(72) Inventors: BARGMANN, Cornelia, I. ; 56 Fairmont Street, Arlington, MA 02174 (US). WEINBERG, Robert, A. ; 25 Copley Street, Brookline, MA 02146 (US).</p> <p>(74) Agent: GRANAHAN, Patricia; Hamilton, Brook, Smith &amp; Reynolds, Two Militia Drive, Lexington, MA 02173 (US).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>																																																																									
<p><b>(54) Title:</b> DETECTION OF POINT MUTATIONS IN NEUGENES</p> <p><b>(57) Abstract</b></p> <p>Oligonucleotide probes reactive with regions of <i>neu</i> oncogenes of mammalian origin in which the mutation causing activation of such oncogenes is contained are described, as are methods for their use in detecting the presence of <i>neu</i> oncogenes in tumor cells. Antibodies specific for gene products encoded by <i>neu</i> oncogenes are also described.</p>																																																																											
<table border="1"> <thead> <tr> <th>Construct</th> <th>Hind III</th> <th>Pvu II</th> <th>Xba I</th> <th>Eco RI</th> <th>Sal I</th> <th>SV40 Poly A</th> <th>Transforming</th> </tr> </thead> <tbody> <tr> <td>pSV2neuN</td> <td>719</td> <td>899 2337</td> <td>3534</td> <td>2387</td> <td></td> <td></td> <td>-</td> </tr> <tr> <td>pSV2neuT</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>+</td> </tr> <tr> <td>pSV2neuF</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> </tr> <tr> <td>pSV2neuB</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> </tr> <tr> <td>pSV2neuH</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>+</td> </tr> <tr> <td>pSV2neuC</td> <td></td> <td></td> <td>X</td> <td>X</td> <td></td> <td></td> <td>+</td> </tr> <tr> <td>pSV2neuTN</td> <td></td> <td></td> <td>Nd</td> <td>9q</td> <td></td> <td></td> <td>-</td> </tr> <tr> <td>pSV2neuNT</td> <td></td> <td></td> <td>Nd</td> <td>Bq</td> <td></td> <td></td> <td>+</td> </tr> </tbody> </table>				Construct	Hind III	Pvu II	Xba I	Eco RI	Sal I	SV40 Poly A	Transforming	pSV2neuN	719	899 2337	3534	2387			-	pSV2neuT							+	pSV2neuF							-	pSV2neuB							-	pSV2neuH							+	pSV2neuC			X	X			+	pSV2neuTN			Nd	9q			-	pSV2neuNT			Nd	Bq			+
Construct	Hind III	Pvu II	Xba I	Eco RI	Sal I	SV40 Poly A	Transforming																																																																				
pSV2neuN	719	899 2337	3534	2387			-																																																																				
pSV2neuT							+																																																																				
pSV2neuF							-																																																																				
pSV2neuB							-																																																																				
pSV2neuH							+																																																																				
pSV2neuC			X	X			+																																																																				
pSV2neuTN			Nd	9q			-																																																																				
pSV2neuNT			Nd	Bq			+																																																																				

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

Detection of Point Mutations in NEU Genes

Description

Background

An increasing body of evidence implicates 5 somatic mutations as causally important in the induction of human cancers. These somatic mutations may accumulate in the genomes of previously normal cells, some of which may then demonstrate the phenotypes associated with malignant growth. Such 10 oncogenic mutations may include a number of different types of alterations in DNA structure, including deletions, translocations and single nucleotide alterations. The latter, also known as point mutations, may frequently intervene in 15 carcinogenesis, in that a variety of mutagenic chemicals induce such mutations. In addition, such mutations may occur spontaneously as a result of mistakes in DNA replication.

Point mutations have been directly implicated 20 in the causation of 10-15% of human tumors. These tumors carry oncogenes of the ras gene family, which differ from their normal cellular counterpart proto-oncogenes by the presence of a point mutation

-2-

at one of several sites in these genes. These mutations represent qualitative changes in the tumor cell genome which distinguish these cells from normal cells and provide a basis for diagnosis of 5 the genetic origin of a tumor under study. Identification of the mutations that have created active oncogenes may provide important diagnostic and prognostic clues for tumor development. For example, a number of mutations has been found to alter 10 the 12th codon of the ras oncogenes, causing replacement of glycine, which is a normally present, by any of a number of alternative amino acid residues. Such amino acid substitutions do not have equivalent effects; some substitutions (e.g., 15 valine) create a potent transforming allele while others (e.g., proline) have only a limited effect on cellular phenotype. Thus, the identity of a particular nucleotide substitution may be a strong determinant of the behavior of the tumor cell (e.g., 20 its rate of growth, invasiveness, etc.). As a result, DNA probes of oncogene mutations have promise as diagnostic reagents in clinical oncology.

Such probes are useful, however, only if a region of a gene of interest in which point mutations are likely to occur has been identified. 25 Unless identification of such a region has been made, it is impractical to use oligonucleotide probes of limited size (e.g., 10-20 nucleotides long) to scan an entire gene, which might well be 30 30,000 or more base pairs long; for example, if a 15-nucleotide probe were used to scan the entire

-3-

length of a gene 33,000 base pairs long, 3000-5000 separate probes would be required.

Thus, although DNA probes of oncogene mutations have potential as diagnostic tools, they cannot be  
5 used effectively unless a discrete region of mutation in the gene, which is causally related to activation of the gene's oncogenic function, has been identified. Without such localization of the  
10 region of mutational activation, use of DNA probes specific for point mutations is impractical.

Disclosure of the Invention

This invention relates to assessment of cellular DNAs to determine whether they carry lesions or alterations in a neu gene which result in the  
15 activation of the proto-oncogene, and its conversion to an oncogene. Oligonucleotide probes specific for nucleotide sequences of the region in which the activation mutation(s) resides, which can be used to determine the presence of an oncogene of the neu  
20 family are described, as are methods for their use.

It has been determined that the rat neu proto-oncogene, which encodes a protein resembling a growth factor receptor, is converted into an oncogene by a single nucleotide alteration or point  
25 mutation. This point mutation was initially seen in a rat neuroblastoma induced by transplacental exposure to a carcinogen (e.g., ethylnitrosourea) and found to affect the amino acid sequence of the transmembrane region of the p185 encoded by the DNA.

-4-

That is, a valine present in the normal protein is replaced by a glutamic acid residue.

Oligonucleotide probes used to assay for similar point mutations suspected to be present in 5 seven additional neu oncogenes, each of which arose in a separate, independently induced tumor, demonstrated the presence of the same activating mutations in all seven neu oncogenes. The same amino acid substitution (glutamic acid replacing valine) 10 resulted in these cells. Further assays with oligonucleotide probes homologous to the neu gene demonstrates that the mutagen methylnitrosourea induces formation of nervous system tumors and activation of neu genes at the same position as 15 shown to occur in the ethylnitrosurea-induced tumors.

The human homolog of the neu gene (also known as c-erbB2 or HER2) is thought to achieve an oncogenic state through the action of a similar 20 mechanism: alteration of a single nucleotide in the normal cellular DNA sequence (the proto-oncogene), resulting in activation of the oncogene. The activating lesion found can be identified in the DNA of a variety of spontaneously arising human tumors 25 through the use of oligonucleotide probes constructed to be specifically reactive with the region of the human neu gene corresponding to the region in the rat neu oncogene known to contain the activating mutations. Identification in human tumor cells of 30 the activating point mutation responsible for conversion of the proto-oncogene into the neu

-5-

oncogene can serve as the basis for construction of oligonucleotide hybridization probes useful in testing human tumor DNAs for the presence or absence of point mutations responsible for activation of neu oncogenes. These hybridization probes can be used in detecting the occurrence of the neu proto-oncogene and of the neu oncogene in cells and in determining the profile of oncogene activations in human tumor specimens. Such oligonucleotide probes are described, as are methods for their use in detecting the presence or absence of neu oncogenes in tumor cells. Antibodies specific for the p185 protein encoded by the neu oncogene, which can be used to detect the occurrence of the neu oncogene, are also described.

Brief Description of the Drawings

Figure 1 is a schematic representation of pSV2neu, created by inserting the neu gene cDNA indicated into the pSV2 expression vector.

Figure 2 presents electrophoretic gel patterns characteristic of cell lines containing pSV2neu constructions.

Figure 3 shows nucleotides 1968 to 2073 and the predicted amino acid sequence for the normal rat neu gene and the transforming rat neu gene.

Figure 4 shows the nucleotide sequence of oligonucleotide probes corresponding in sequence to a) the wild type (normal), b) the mutant neu version of the neu gene, c) DNA from DHFR G8, and d) a

-6-

modified version of the mutant neu gene in which there is a T to G transversion.

Figure 5 shows electrophoretic gel patterns after hybridization of DNA from neu transfectants 5 with oligonucleotide probes.

Figure 6 shows electrophoretic gel patterns after hybridization of DNA from tumor cell lines and normal BDIX DNA with oligonucleotide probes.

Figure 7 shows electrophoretic gel patterns 10 after probing of fourteen transfectants containing ten independent activated neu genes with either the oligonucleotide corresponding to the normal gene (proto-oncogene) (top) or the oligonucleotide corresponding to the transforming gene (oncogene) 15 (bottom).

#### Detailed Description of the Invention

It is now known that cellular genes other than the ras genes can be converted into oncogenes by point mutations. It has recently been shown that 20 the rat neu proto-oncogene, which encodes a protein resembling a growth factor receptor, can also be converted into an oncogene by a single nucleotide alteration. Thus, it has been shown that the neu proto-oncogene (i.e., the nucleotide sequence 25 present in the normal genome of normal non-tumor cells) can undergo mutational activation into its corresponding oncogene (i.e., the nucleotide sequence whose expression within a cell causes its conversion from a normal cell into a tumor cell) by 30 a single nucleotide substitution. This point

-7-

mutation, initially demonstrated in a rat neuroblastoma induced by transplacental exposure to ethylnitrosourea, has also been shown to occur in seven other neu oncogenes, each of which arose in a 5 separate, independently induced by ethylnitrosourea exposure. Detection of the point mutations relied on the use of oligonucleotide probes specific for the region initially shown to contain the activating mutation. In all cases, the same amino acid 10 substitution resulted: a valine normally present in the transmembrane region of the encoded p185 protein was replaced by a glutamic acid residue. This finding suggests that nucleotide substitution at only a limited number of sites in the neu 15 proto-oncogene will result in its becoming an active oncogene.

Transfectants which arose from DNAs from ten methylnitrosourea-induced nervous system tumors which contained activated neu genes have also been 20 shown to have the identical alteration in their DNA and are presumed to have the same sequence change as that present in the ethylnitrosourea-induced tumors, based on their differential hybridization to an oligonucleotide probe corresponding to the 25 transforming gene. Thus, oligonucleotide probes homologous to the neu gene have been shown to be able to detect activated neu genes in tumors induced by exposure to methylnitrosourea. In addition, this demonstrates that both mutagens cause activation of 30 neu genes at the same position and that activated neu genes can arise in both BDIX rats

-8-

(ethylnitrosourea-induced tumors) and Buffalo rats (methylnitrosourea-induced tumors).

Human versions of the rat neu genes have been isolated and are also referred to as c-erbB2 or

5 HER2. Yamamoto, T. et al., Nature, 319:230-234 (1986); Coussens, L. et al., Science, 230:1132-1139 (1985). The DNA sequences of both the rat and the human clones predict a 1260 amino acid protein product of the neu gene.

10 Mutational activation of the human homologs of the rat neu genes, referred to here as the human neu oncogenes, is thought to occur through a similar mechanism: single nucleotide substitution or point mutation in the human neu gene. It is highly likely  
15 that the single nucleotide substitution occurs in the region of the human neu proto-oncogene that corresponds with the region in the rat neu oncogene shown to contain the activating mutations. It is possible to determine the presence or absence of the  
20 activating lesion in the DNA of a variety of spontaneously arising human tumors through the use of oligonucleotide probes specifically reactive either with regions unique to the neu oncogene or with regions unique to the corresponding neu  
25 proto-oncogene. That is, hybridization probes can be constructed which will react (hybridize) with a nucleotide sequence occurring in either a neu oncogene or its corresponding proto-oncogene (but not in both). Such probes can be used to test human  
30 tumor DNAs for the occurrence of a point mutation responsible for activation of the neu oncogene. For

-9-

example, radiolabelled oligonucleotide probes can be used in the Southern blot hybridization procedure to detect activation of the neu oncogene in human tumors of clinical interest.

5      Because the p185 proteins encoded by neu oncogenes are different from those encoded by their corresponding proto-oncogenes, it is also possible to develop serological reagents, such as polyclonal antibodies or monoclonal antibodies, which are  
10     specific for the altered or the normal amino acid sequences in such proteins. These reagents can be used to provide highly sensitive tests for the presence or absence of neu oncogenes by detecting the occurrence of the mutated or altered gene  
15     products they encode.

The approach described has been used successfully in identifying the point mutation which causes activation of the neu proto-oncogene in DNA from a chemically induced (i.e., ethylnitrosourea-induced)  
20     rat neuroblastoma. It has also been used to verify the occurrence of the same activating point mutations in seven other neu oncogenes (each having arisen in a separate, independently (chemically) induced tumor).

25     In addition, the approach has been used to detect the presence in DNAs from methylnitrosourea-induced nervous system tumors of Buffalo rats. It has been demonstrated that all of the transfected neu genes bore the identical alteration as occurs in  
30     the DNA from the ethylnitrosourea-induced tumor. The approach described can be used, with

-10-

modification, in identifying point mutations which cause activation of human neu oncogenes. In addition, it is possible to develop serological reagents, such as polyclonal antibodies or 5 monoclonal antibodies specific for the altered or the normal amino acid sequences of the proteins encoded, respectively, by a neu oncogene or its corresponding proto-oncogene. These reagents can be used to test cells for the occurrence of the encoded 10 protein and thus for the presence or absence of the neu oncogene.

The neu gene family

Exposure of perinatal BDIX rats to a single dose of the alkylating agent ethylnitrosourea leads 15 to a high incidence of neuroectodermal tumors.

Rajewsky, M.F. et al., In: Origins of Human Cancer, Cold Spring Harbor Laboratory, 709-726 (1977); Rajewsky, M.F., In: Recent Results in Cancer Research 84:63-76 (1983). Up to 95% of animals mutagenized 20 transplacentally after the fifteenth day of gestation or injected directly with ethylnitrosourea up to ten days after birth will develop central and peripheral nervous system tumors after a dose- and strain-dependent latency time. These tumors and the 25 cell lines derived from these tumors display the characteristics of a wide variety of neural and glial cell types. Schubert, D., Nature, 249:224-227 (1974).

DNA isolated from four independently derived 30 tumor cell lines of this type contains activated oncogenes which can be detected in an NIH 3T3 focus

-11-

forming assay. The majority of oncogenes detected in this assay have been shown to be genetically altered versions of one of the three closely related ras genes (Varmus, 1984). However, the gene transferred from these neuro/glioblastomas is unrelated to the ras genes and has been designated neu.

10 Neu was first recognized to be a distinct gene by its association with the 185,000 dalton tumor antigen, p185, which is displayed on the surface of transfected cells. Neu is related in DNA sequence to the erbB gene, which encodes the epidermal growth factor (EGF) receptor, and antisera raised against the EGF receptor show some cross-reactivity with p185. However, detailed analysis has shown that neu 15 bears only limited homology to erbB and that the two genes reside on different chromosomes. Schechter, A.L. et al., Science, 229:976-978 (1985). Thus, the neu gene is related to, but distinct from, the gene which encodes the EGF receptor.

20 cDNA clones of the neu oncogene have been isolated from cell lines transformed by this gene. Bargmann, C.I. et al., Nature, 319:226-230 (1986). Human versions of the same gene have also been isolated and termed variously c-erbB2 or HER2. The 25 DNA sequences of these rat and human clones predict a 1260 amino acid protein product of the neu gene which is colinear with and 50% identical to the predicted amino acid sequence of the EGF receptor. By analogy to the EGF receptor, the neu product 30 appears to be a transmembrane protein consisting of a cysteine-rich extracellular region of 650 amino

-12-

acids, a transmembrane domain, and an intracellular portion of 580 amino acids consisting in part of a tyrosine kinase domain.

Biochemical studies of the p185 protein support 5 these conclusions. p185 is glycosylated and accessible to antisera in intact cells, which is consistent with its being localized at the cell surface. It also has an associated tyrosine specific protein kinase activity. p185 does not, however, bind EGF 10 and thus appears to be the receptor for an as yet unidentified growth factor.

Isolation of clones of normal and transforming alleles of the rat neu gene

Biologically active genomic clones of normal 15 and transforming alleles of the rat neu gene have recently been isolated. Hung, M.-C, et al., Proceedings of the National Academy of Sciences, U.S.A., 83:261-264 (1986). Structural comparison of these clones revealed no evidence of gross 20 rearrangements, suggesting that subtle genetic alterations were responsible for activation of the neu oncogene. Comparable levels of p185 were shown to be expressed in nontransformed cell lines containing the normal allele and in transformed cell 25 lines containing the mutant allele, suggesting that the alteration responsible for the activation of neu did not lead to deregulation of expression of the gene. Such results implicate a transforming lesion within the encoded protein p185, which should be 30 represented in cDNA versions of the gene.

-13-

Comparison of cDNA clones of the normal neu gene and transforming cDNA clones

To determine the effect of the alteration responsible for activation of the neu gene, a 5 comparison was made of the previously isolated transforming cDNA clone, DNAs from three other ethylnitrosourea-induced activations of the neu gene and a cDNA clone of the normal allele of neu.

Isolation of a normal neu cDNA clone

10 It was first necessary to isolate a normal neu cDNA clone. To do so, a cDNA library was constructed using RNA from the cell line DHFR G8. Hung, M.-C., et al., Proceedings of the National Academy of Sciences, U.S.A., 83:261-264 (1986). The 15 DHFR cell line was made by transfecting a genomic cosmid clone containing a complete normal neu gene from the BDIX strain of rat into NIH 3T3 cells. These cells express high levels of the neu gene product, p185, and a high level of the neu RNA 20 transcribed from the transfected gene. cDNA clones were made by the S1 snapback technique, tailed with dCTP using terminal transferase, and inserted into dG-tailed pBR322 at the PstI site. Thirty recombinant plasmids reactive with neu probes were isolated. 25

These plasmid clones were compared by restriction mapping to a full length cDNA clone of an activated neu oncogene. While these normal cDNA clones have common sequences with the previously 30 identified transforming cDNA clones, none contained the entire coding region of neu. A clone containing

-14-

the entirety of the neu coding region was constructed, however, by in vitro recombination of two partial, overlapping clones which share a unique NaeI site. The 5' end of the resulting clone was 5 sequenced to verify the presence of the initiation codon for the neu-encoded p185 protein.

This normal neu clone was inserted into the pSV2 expression vector to create pSV2neuN, as shown in Figure 1. Mulligan, R.C. et al., Nature, 277:  
10 108-114 (1979). A transforming neu cDNA clone derived from the B104-1-1 cell line, which is a secondary transfectant of an activated rat neu gene, was inserted into pSV2 to create a plasmid designated as pSV2neuT (Figure 1). pSV2neuT was highly  
15 active in a focus-forming assay on NIH 3T3 cells or Rat 1 fibroblasts. This assay measures the ability of DNA molecules that have been introduced into cells by the transfection to convert such cells, growing in monolayer culture to a transformed state,  
20 causing descendants of these cells to form a cluster or focus of morphologically transformed cells in an area of the cell monolayer. However, when the normal neu cDNA, also inserted into the pSV2 vector, was transfected into NIH 3T3 cells using identical  
25 conditions, no foci were observed.

Comparison of p185 production by transformed and nontransformed cells

Cell lines containing the pSV2neuN or pSV2neuT plasmids were isolated by cotransfection with  
30 pSV2neo (referred to hereafter as the neo-r marker) and selection of G418. Southern, P.J. and P. Berg,

-15-

Journal of Molecular and Applied Genetics, 1:327-341 (1982). Cell lines expressing the pSV2neuT construct were morphologically transformed and refractive; those containing pSV2neuN were flat and

5 nontransformed in morphology. These cell lines were metabolically labeled with  $^{32}\text{P}$  orthophosphate and their lysates incubated with a monoclonal antibody that specifically precipitates the rat neu gene product. As shown in Figure 2B, lanes c, d, and i,

10 the levels of labeled p185 were comparable in the transformed and nontransformed cells. These results are consistent with earlier work suggesting that neu has been activated by a mutation in the coding region of the gene rather than one which deregulates

15 expression. Hung, M.-C. et al., Proceedings of the National Academy of Sciences, U.S.A., 83:261-264 (1986).

Identification of the DNA sequences responsible for neu gene activation

20 Identification of sequences responsible for the transforming activity of the pSV2neuT clone was carried out by using recombinants between this clone and the pSV2neuN clone carrying the normal allele. The recombinants were constructed by ligation of

25 appropriate cloned DNA segments. Figure 1 shows the structure of a series of clones which delineate the region of neu that carries the activating mutation. The structure of each recombinant clone shown was verified by restriction mapping. In each case, at

30 least two independent plasmid isolates were tested for the ability to morphologically transform NIH 3T3

-16-

cells. All recombinant clones were cotransfected with the neo-r marker and the morphology of the resulting G418-resistant colonies was scored. Morphologically nontransformed colonies were tested 5 to ensure that they were expressing structurally intact p185 protein from the acquired cDNA clones.

Clones pSV2neuF and pSV2neuB, which contain the first 719 and 1899 nucleotides, respectively, of the transforming clone fused to the remaining sequences 10 of the normal clone (Figure 1), were not transforming, although they did direct the synthesis of p185. Clone pSV2neuH, which contained transforming neu sequences from the 5' end of the gene up to nucleotide 2387 and normal neu sequences thereafter, gave 15 foci upon transfection and yielded transformed colonies indistinguishable from those generated by the parental pSV2neuT clone. pSV2neuC was also transforming. It contained an XbaI fragment from nucleotide 2337 to nucleotide 3534 of the normal neu 20 gene, which replaced the corresponding portion of the transforming cDNA. These results indicate that the normal cDNA and the transforming cDNA differ in a sequence between nucleotides 1899 and 2337 and that the presence of this sequence in the transforming 25 clone is necessary for transformation.

In order to prove that this sequences is also sufficient for transformation, the reciprocal constructs pSV2neuTN and pSV2neuNT (Figure 1) were constructed and tested by transfection into NIH 3T3 30 cells and Rat 1 fibroblasts. pSV2neuTN contained the entire transforming cDNA with the exception of

-17-

nucleotides 1899 to 2387, defined by NdeI and BgII sites, which are derived from the normal neu clone. pSV2neuNT contained the entire normal neu cDNA sequence except for the corresponding 488 nucleotides, which were replaced by those from the transforming clone. In parallel experiments, pSV2neuNT gave comparable numbers of foci to pSV2neuT, the parental transforming clone; pSV2neuTN, pSV2neuN, and mock transfected controls yielded no foci.

10 These experiments demonstrate that the essential genetic differences between the normal and transforming clones reside within this 488 nucleotide fragment.

The data shown in Figure 2 support these conclusions. G418-resistant cell lines isolated by cotransfection of the pSV2neu plasmids and the selectable neo-r gene are shown in Figure 2A. Lines containing pSV2neuTN or pSV2neuN are morphologically flat and indistinguishable from lines transfected with the neo-r gene alone. In contrast, cells containing pSV2neuNT and pSV2neuT are highly refractive and very similar to one another in morphology. These cell lines were metabolically labeled with <sup>32</sup>P-orthophosphate and the resulting lysates incubated with anti-p185 monoclonal antibody 16.4. Drebin, J.A. et al., Nature, 312:545-548 (1984). Figure 2B shows the levels of p185 expressed in representative cell lines containing pSV2neuN (lanes c and d), pSV2neuT (lane i), pSV2neuTN (lanes e and f), and pSV2neuNT (lanes g and h). Lysates from DHFR G8 and B104-1-1 cells (lanes b and j), the

-18-

cells lines from which the normal and transforming cDNAs were isolated, were also analyzed. Although individual cell clones show a wide range of p185 levels, it is clear that there are similar ranges of 5 p185 expression in both the normal and transformed cells. No p185 is found in lines transfected with the neo-r marker clone alone (lane a). Thus, the differences in these cells must be accounted for by 10 intrinsic differences in the properties of the p185 proteins that they express.

Definition of the mutation distinguishing the normal neu allele and the activated neu gene

The complete DNA sequence of the coding region of the transforming neu cDNA has been determined.

15 Bargmann, C.I. et al., Nature, 319:226-230 (1986). To define the precise mutation that distinguishes the two alleles, the DNA sequence of the region between nucleotides 1899 and 2387 was determined for the normal neu cDNA. Only a single difference was 20 found between this sequence and that previously determined for the transforming clone. At nucleotide position 1012 there is an A in the oncogene clone, while the normal clone carries a T in this position. As a result, the predicted amino acid 25 present at residue 664 of the encoded p185 is affected; a valine found in the normal protein is replaced by a glutamic acid in the oncogenic version. Figure 3 shows the DNA and predicted amino acid sequence of nucleotides 1968 to 2073 for both 30 the normal neu gene and the transforming neu gene.

-19-

The presumed mutation falls within the putative transmembrane domain of the neu gene product, p185.

Genomic clones of normal and transformining alleles of neu have been previously isolated. These 5 clones were used to independently verify the nucleotide difference seen in the cDNAs. Such corroborative data served to exclude the possibility that the observed difference in the cDNAs arose during cDNA cloning. Sequencing of subclones of the genomic 10 versions of the two alleles confirmed that the same T to A substitution was present in these genomic clones. This indicates that the mutation, a T to A transversion, arose somatically during creation of the B104 neuroblastoma tumor or cell line.

15 Determination of activation of independent neu oncogenes

Earlier results had shown that DNAs prepared from four out of six neuro/glioblastoma cell lines displayed activated neu oncogenes in a NIH 3T3 focus 20 assay. Shih, C. et al.: Nature, 290:261-264 (1981). These six cell lines had been derived by transplacental mutagenesis of BDIX rat embryos with ethylnitrosourea. These independent activated neu genes were evaluated to see if they contain the same 25 activating mutation. DNAs from transfecants containing these neu genes were hybridized with oligonucleotide probes which would recognize preferentially one or the other allele of the neu gene. This technique has been successful in identifying 30 various activated alleles of ras genes. Bos, J.L.

-20-

et al., Nature, 315:726-730 (1985); Zarbl, J. et al., Nature, 315:382-385 (1985).

Oligonucleotides corresponding in sequence either to the wild type or the mutant neu version of 5 the neu gene were synthesized. The sequence of these two 20-mers is given in Figure 4. These 20-mers were then hybridized under stringent conditions (2 degrees below the calculated  $T_m$  of a perfect duplex) to dried agarose gels containing 10 DNAs which had been digested with appropriate restriction endonucleases. The 20-mer corresponding to the wild type sequences hybridized approximately ten times as well to pSV2neuN as it did to pSV2neuT. In contrast, the oligonucleotide whose sequence 15 derived from the transforming allele preferentially hybridized to pSV2neuT by the same factor.

DNA was isolated from transfec- 20 tants carrying the four independently activated neu oncogenes described above and cleaved with HindIII. The resulting fragments were resolved on a 1% agarose gel. The agarose gels were incubated under conditions identical to those used in analysis of the cloned DNAs described above shown in Figure 4. DNA from DHFR G8, which contains about 50 copies per 25 genome of the normal genomic neu gene, was included as a control.

Figure 5A shows hybridization of the transfec- 30 tant DNAs with the oligonucleotide corresponding to the wild type sequence. A strong signal appears in DHFR G8 DNA, which has introduced copies of the normal neu gene (lane b). Considerably weaker

-21-

signals can be seen in lanes containing the neu-transformed transfectant DNAs (lanes c-f) and in untransfected NIH 3T3 cells (lane a). Figure 5B shows an identical gel prepared in parallel probed 5 with the oligonucleotide containing the mutant sequence. DHFR G8 DNA reacts only weakly with this probe (lane b) but all neu-transformed transfectant DNAs (lanes c to f) yield strong signals with this probe. The transfectant DNA shown in lane d has a 10 smaller neu-homologous HindIII fragment than the other transfectants due to truncation of the trans-fected gene at the 3' end.

A low level of reactivity between the wild type probe and the transfectants is probably due to 15 cross-reactivity of the probe, since it is comparable to the signal seen upon analysis of cloned pSV2neuT DNA with the same probe (compare Figure 4 lanes b and d with lanes c-f in Figure 5A and 5B).

In order to control for differences in signal 20 intensity due to DNA loading and transfectant copy number, the gel in 5B was stripped of probe and rehybridized with an oligonucleotide probe from a different part of the neu gene. The transfectant cell lines may contain different copy numbers of the 25 rat neu gene due to variable amplification during the process of transfection. The results of this hybridization are shown in Figure 5C. Comparison of corresponding lanes in Figures 5A, B, and C shows that DNAs of all neu oncogene transfectants exhibit 30 stronger hybridization with the mutant probe than with the wild type probe, and that the extent of

-22-

their hybridization with the mutant probe correlates well with the copy number of the neu gene present in the various DNAs.

Although these data strongly suggest that all 5 of the activated neu genes studied have alterations at the same nucleotide position, it was not clear whether the mutations involved the same T to A transversion in all cases. A T to G transversion might give the same pattern of hybridization, since 10 it would cause an A/G mismatch with the wild type oligonucleotide and a relatively stable G/T mismatch with the mutant oligonucleotide. To address this possibility, a third 20-mer was synthesized with the sequence shown in Figure 4. This oligonucleotide 15 was incubated under hybridizing conditions with the gel analyzed in Figure 5A after the initial probe had been removed. This oligonucleotide did not hybridize preferentially to the transfectant DNAs under stringent conditions (Figure 5D). Thus, the 20 alteration in each of these activated neu genes is probably the same T to A transversion.

That the point mutation was generated during tumorigenesis and thus did not reflect preexisting polymorphism in the rat genome or activation during 25 the transfection process was also confirmed. DNA was isolated from BDIX rat liver and from the four rat tumor cell lines which were derived from BDIX rats and yielded activated neu genes in a transfection assay. Duplicate gels were probed either 30 with the wild type or the mutant oligonucleotide (Figure 6). BDIX liver DNA reacts well with the

-23-

wild type but not with the mutant oligonucleotide (Figure 6, lanes a and f). In contrast, the four tumor cell lines react only with the mutant oligonucleotide (Figure 6, lanes b-e and i-l). This 5 demonstrates that the T to A transversion at nucleotide 2012 arose in the generation of the tumor or tumor cell lines. It also seems that the tumor cell lines are hemizygous or homozygous for the activated allele of the neu gene. Loss of the normal allele 10 may have occurred during tumorigenesis or in passage of the tumor cell lines. A similar loss or under-expression of the normal ras alleles has been observed in several tumors and tumor cell lines that contain oncogenic versions of these ras genes. 15 Capon, et al. Nature, 304:507-513 (1983); Guerrero, I et al., Proceedings of the National Academy of Sciences, U.S.A., 82:7810-7814 (1985).

Multiple independent activations of neu

Chemical carcinogenesis, though provoked by 20 apparently randomly acting agents, often results in specific genetic changes in the resulting tumor cells. Neu appears to be activated by the same nucleotide change in each of the four of the transforming neu alleles analyzed. Each of these alleles 25 was isolated from a neuro- or glioblastoma that arose from transplacental exposure to the alkylating agent ethylnitrosourea. Schubert, D. et al., Nature, 249:224-227 (1974). Neu is also activated at the same residue in four independent nervous 30 system tumors induced by the related alkylating agent methylnitrosourea.

-24-

Similarly, extensive study of methylnitrosourea-induced mammary carcinogenesis in Buf/N rats has shown that among nearly 100 independent resulting tumors, all contain H-ras oncogenes activated by the identical G to A transition at residue 35. Sukumar, S. et al., Nature, 306:658-661 (1983); Zarbl, H. et al., Nature, 315:382-385 (1985). Other examples of specificity of activation include

5 dimethylbenzanthracene-induced papillomas with activated H-ras genes in genetically susceptible Sencar mice and thymic lymphomas induced by gamma irradiation or methylnitrosourea, which yield transfectable K-ras and N-ras oncogenes;

10 respectively. Balmain, A. and I.A. Pragnell, Nature, 303:72-74 (1983); Guerrero, I. et al., Proceedings of the National Academy of Sciences, U.S.A., 81:202-205 (1984). The K-ras oncogenes detected in the former case appear to have the same

15 activating mutation in at least three out of four tumors examined. It is interesting to note that the administration of the same mutagen, methyl-nitrosourea, under different conditions leads to the specific activation of H-ras in mammary tumors,

20 N-ras in thymic lymphomas, and neu in neurectodermal tumors. Guerrero, I. et al., Science, 225:1159-1162 (1984).

30 The carcinogen which induces each of these tumors must initially inflict widespread damage to the cellular DNA. The final mutation detected is, however, highly specific. Clearly, strong

-25-

biological forces must act during multistep carcinogenesis to select the outgrowth of cells bearing the genetic lesions observed in the ensuing tumors. It appears that only a small proportion of 5 cellular genes can be converted into biologically active oncogenes. Within one of these genes, only a few of many possible mutations will yield an actively transforming oncogene. The relatively rare mutations which do generate oncogenes are enriched 10 first because they must confer a selective advantage to the tumor, and later because they can be detected in the focus-forming assay.

The repeated appearance of a specific lesion in one tumor type suggests the presence of additional 15 forces selecting among the possible activating mutations. The nature of the activating mutation must be strongly influenced by the chemical reactivities of the carcinogen. For example, different mutagens used to induce thymomas lead to 20 different activated genes in the resulting tumors. Similarly, mammary carcinomas induced by dimethylbenzanthracene contain a different specific alteration from those induced by methylnitrosourea.

The reactivity of ethylnitrosourea, the agent 25 which induced the described neuroblastomas, allows it to form a number of different adducts in DNA. Singer, B. and J.T. Kusmierenk, Annual Review of Biochemistry, 52:655-693 (1982). Among these, an adduct causing G to A transition mutations is well 30 described. Rajewsky, M.F., Recent Results in Cancer Research, 84:63-76 (1983). Such mutations have been

-26-

found repeatedly as the activating lesions in the H-ras oncogenes of mammary carcinomas induced by the related carcinogen methylnitrosourea. Zarbl, H. et al., Nature, 315:382-385 (1985). The presently 5 described mutations are, however, T to A transversions, the creation of which must be explained by alternative mechanisms involving another one of the many adducts formed after administration of these alkylating agents. This type of mutation is not 10 without precedent: two other ethylnitrosourea-induced mutations isolated after germ-line mutagenesis of mice has also been shown to be T to A transversions. Popp, R.A. et al., Genetics, 105: 157-167 (1983); Lewis, S.E. et al., Proceedings of 15 the National Academy of Sciences, U.S.A., 82:5829- 5831 (1985). An N-ras oncogene isolated from a methylnitrosourea-induced lymphoma has been found to be activated by a C to A transversion suggesting that several different adducts induced by alkylating 20 agents can lead to mutations. Guerrero, I. et al., Proceedings of the National Academy of Sciences, U.S.A., 82:7810-7814 (1985).

Examination of tumor DNAs from Buffalo rats with oligonucleotide probes homologous to the neu gene.

25 Sukumar and Barbacid (National Cancer Institute, Bethesda) have isolated ten methylnitrosourea-induced nervous system tumors of Buffalo rats which contain activated neu genes. Transfectants which arose from these tumor DNAs were

-27-

assessed to compare the mutation in these neu genes to that found in the tumors previously described.

This was carried out in the following manner: Fifteen transfectants containing ten independent activated neu genes are shown in Figure 7 (tracks 1-14). Duplicate gels were probed with the oligonucleotide probes described above. That is, they were probed either with the normal oligonucleotide (Figure 7, top) or the 10 oligonucleotide corresponding to the transforming gene (Figure 7, bottom). NIH DNA (track N), DHFR G8 DNA (track G) (high copy of the normal neu gene), B104-1-1 DNA (track B) (high copy of the transforming neu gene) and two Buffalo rat tumors 15 which do not contain active neu genes (tracks c1 and c2) were included as controls.

All of the transfected neu genes bore the identical alteration as that in B104-1-1 DNA, the cell line from which the transforming neu cDNA clone 20 described above was derived. Based on their differential hybridization to the oligonucleotide corresponding to the transforming gene, the transfected neu genes are presumed to have the same sequence change as the B104-1-1 neu gene. These 25 results provide ten independent examples of activated neu genes detected with the oligonucleotide; demonstrate that a second mutagen, methylnitrosourea, leads to the activation of neu genes at this position in a similar way as 30 ethylnitrosourea; and demonstrate that activated neu genes arise in Buffalo rats as well as BDIX rats.

-28-

Oligonucleotide-directed mutagenesis

Oligonucleotide-directed mutagenesis was used to substitute a glutamine residue for the valine residue normally found at amino acid position 664.

5 When this mutated neu gene was inserted into an expression vector (Psi 2) and transfected into or infected into recipient (NIH 3T3) cells, 100% of the stable cell lines generated were transformed.

10 Korman, A. and R.C. Mulligan, Proceedings of the National Academy of Sciences, USA (April 1987). (In contrast, 0.1% of recipient cells transformed with the normal neu gene (proto-oncogene), which encodes a protein including a valine residue at amino acid position 664, were transformed.) Thus, like

15 glutamic acid, glutamine at position 664 leads to generation of a transforming neu gene, and mutations detected with an oligonucleotide probe that would recognize glutamine would be presumed to be transforming mutations. Substitution of an aspartic acid residue at position 664, followed by

20 transfection or infection into nontransformed cells, led to the transformed phenotype in 2-3% of the recipient cells. This appears to represent a weakly transforming allele of the neu gene, whose

25 overexpression must be coupled to the mutation for transformation to occur.

Identifying the activation mutation in human neu genes

30 Although the discussion to this point, as well as the experimental work described, has been related

-29-

to the point mutation responsible for activation of the rat neu oncogene, it is possible to use the same approach in identifying the corresponding activation mutation in human neu genes and in detecting the 5 presence of a neu oncogene (or its corresponding proto-oncogene) in human tumor cell DNAs. For example, oligonucleotide probes can be constructed which are specifically reactive with the region of a human neu gene which corresponds to the region shown 10 to contain the point mutation responsible for the activation of the rat neu oncogene. An example of a probe which can be constructed is one based on a single nucleotide difference between a neu oncogene and its proto-oncogene, this single nucleotide 15 alteration being responsible for conversion of the neu proto-oncogene into its activated oncogene form. These probes, which can be of any length, but will generally be 15 to 20 nucleotides long, can then be used to analyze a tumor cell genome, to determine 20 whether it carries lesions (mutations) in the neu oncogene and to determine their precise location, as described above for the rat neu oncogenes.

Detecting the presence of a neu oncogene

An assay for detecting carcinogenesis caused by 25 mutation of a neu proto-oncogene into neu oncogene comprises employing a labelled oligonucleotide probe specific for a nucleotide sequence present in (or transcribed from) the proto-oncogene or the oncogene, but not the other. An assay for 30 carcinogenesis in human cells can be performed by

-30-

isolating DNA from the test cells and contacting the DNA with a labelled polynucleotide probe specific for either an oncogenic or proto-oncogenic sequence in the DNA and thereafter determining whether the 5 probe hybridizes to the DNA. After being radio-labelled, these probes can be used, for example, in the Southern blot procedure to assess tumor cell DNAs for the occurrence of such point mutations. This type of assay can be used in a clinical context 10 as a diagnostic tool to determine the profile of oncogenes activated in human tumor DNAs. The assay would be highly specific because it is capable of detecting single nucleotide alterations in genes of the neu family, thus providing very definitive 15 information about the tumor cells being assayed.

Reagents for employing these oligonucleotide probes can be assembled into a kit. Thus, a kit might contain, in addition to the probe, one or more buffers, reagents for labelling the probe, reagents 20 employed in Southern or other blots, etc.

Because of the change in amino acid sequence of the product protein encoded by a proto-oncogene from the product encoded by an oncogene, it is possible to detect either by specific serological reagents. 25 The serological reagents can be specific for the normal, neu proto-oncogene-specified amino acid sequence at this site of the protein, or be specific for the altered oncogene-specified amino acid sequence at this site of the protein. Other serological reagents could be employed that are reacted 30 with a region of the protein that is unaltered, and

-31-

consequently reactive with either normal or abnormal forms of the encoded protein.

Using cloning techniques, significant amounts of the protein encoded for by the normal site of the 5 proto-oncogene, or by the altered site of the oncogene, can be isolated. Such protein segments could be used to produce antibodies by standard antibody production techniques. Thus, for producing polyclonal antibodies, such proteins would be employed 10 to immunize a host, such as a rabbit or a rat, and antibodies to the protein would be collected from serum obtained from the host.

Alternatively, monoclonal antibodies could be produced employing cells which produce antibodies to 15 the protein produced by the isolated gene segment in typical fusion techniques for forming hybridoma cells. Basically, these techniques involve the fusing of the antibody-producing cell with a cell having immortality, such as a myeloma cell, to 20 provide a fused cell hybrid which has immortality and is capable of producing the desired antibody (in this case, an antibody to the normal or altered segment of protein coded for by the isolated gene segment). The hybrid cells are then cultured under 25 conditions conducive to the production of antibody after which antibody is collected from the cell culture medium. Such techniques for producing monoclonal antibodies have been well described in the literature. See, for example, U.S. Patent Nos. 30 4,172,124 and 4,196,265, issued to Hilary Koprowski

-32-

et al., the teachings of which are hereby incorporated by reference.

Equivalents

Those skilled in the art will recognize, or be  
5 able to ascertain using no more than routine  
experimentation, many equivalents to the specific  
embodiments of the invention described specifically  
herein. Such equivalents are intended to be  
encompassed in the scope of the following claims.

-33-

CLAIMS

1. An oligonucleotide probe specifically reactive with the region of mutational activation in a neu gene of mammalian origin.
- 5 2. An oligonucleotide probe of Claim 1 which is labelled.
3. An oligonucleotide probe of Claim 2 which is radiolabelled.
- 10 4. An oligonucleotide probe which is specifically reactive with a nucleotide sequence present in a neu oncogene of mammalian origin but not present in the proto-oncogene for that neu oncogene.
- 15 5. An oligonucleotide probe of Claim 4 which is labelled.
6. An oligonucleotide probe of Claim 5 which is radiolabelled.
- 20 7. An oligonucleotide probe comprising from 15 to 20 nucleotides, the nucleotide sequence of said probe being specifically reactive with a region of a neu oncogene of mammalian origin which differs from the same region of the proto-oncogene of said oncogene by a single nucleotide, said region of the neu oncogene

-34-

containing the mutation causing activation of the neu oncogene.


8. An assay for carcinogenesis in mammalian cells caused by mutation of a neu proto-oncogene into a neu oncogene, comprising:
  - a. contacting DNA isolated from the cells with an oligonucleotide probe specific for a nucleotide sequence unique to either the neu proto-oncogene or the neu oncogene, under conditions appropriate for hybridization; and
  - b. determining whether hybridization occurs between said DNA and said probe.
9. A method of detecting carcinogenesis in tumor cells, comprising:
  - a. isolating DNA from the tumor cells;
  - b. contacting said DNA with an oligonucleotide probe, said probe being comprised of nucleotides reactive with the region of a neu gene which includes the activating mutation, under hybridizing conditions; and
  - c. determining whether hybridization occurs between said DNA and said probe.
10. A method of detecting the presence of a neu oncogene in tumor cells, comprising:
  - a. isolating DNA from the tumor cells;

-35-

- b. contacting said DNA with an oligonucleotide probe reactive with a nucleotide sequence present in a neu oncogene but not present in the proto-oncogene for the neu oncogene, under conditions appropriate for hybridization; and  
5  
c. determining whether hybridization occurs between said DNA and said probe.
11. An antibody specific for the gene product  
10 encoded by a neu oncogene.
12. An antibody of Claim 11 which is monoclonal.
13. An antibody specific for the protein encoded by a nucleotide sequence present in a neu oncogene of mammalian origin but not present in the  
15 proto-oncogene of said neu oncogene.
14. An antibody specific for the protein encoded by a region of a neu oncogene of mammalian origin which differs from the same region of the proto-oncogene of said oncogene by a single  
20 nucleotide, said region of the neu oncogene containing the mutation causing activation of the neu oncogene.

1/7

## FIG. I



SUBSTITUTE SHEET

FIG. 2A





FIG. 2B

a b c d e f g h i j  
- + - + - + - + - + - +



p185—



3/7

## FIG.3

normal

|              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |        |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--------|
| glu          | gln | arg | ala | ser | pro | val | thr | phe | ile | ile | ala | thr | val | :   | gly | val | aa 666 |
| GAG          | CAG | AGA | GCC | AGC | CCG | GTG | ACA | TTC | ATC | ATT | GCA | ACT | GTA | :   | GGC | GTC |        |
| transforming |     |     |     |     |     |     |     |     |     |     |     |     | GAG | glu |     |     |        |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |        |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--------|
| leu | leu | phe | leu | ile | leu | val | val | val | val | gly | ile | leu | ile | lys | arg | arg | aa 683 |
| CTG | CTG | TTC | CTG | ATC | TTA | GTG | GTG | GTC | GTT | GGA | ATC | CTA | ATC | AAA | CGA | AGG |        |

SUBSTITUTE SHEET

4/7

## FIG. 4

A) ACGCCCAC TACAGTTGCAAT      nucleotides 1999-2018, wild-type sequence

\*  
B) ACGCCCTCTACAGTTGCAAT      nucleotides 999-2018, T<sub>2012</sub> to A

C) CCGTCCTCAGCTGTGACC      nucleotides 996-1013, control probe




\*  
D) ACGCCCCCTACAGTTGCAAT      nucleotides 1999-2018, T<sub>2012</sub> to G

SUBSTITUTE SHEET

5/7

## FIG.5

a b c d e f a b c d e f




SUBSTITUTE SHEET

6/7

FIG. 6

a b c d e f g h i j



SUBSTITUTE SHEET


7/7

## FIG.7

N G B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 c1 c2



N G B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 c1 c2





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


|   |  |    |  |
|---|--|----|--|
| (51) International Patent Classification <sup>4</sup> :<br>C12Q 1/68, C12N 15/00<br>G01N 33/574 |  | A3 | (11) International Publication Number: WO 87/07646<br>(43) International Publication Date: 17 December 1987 (17.12.87) |
|---|--|----|--|

|  |  |
|--|--|
| (21) International Application Number: PCT/US87/01282<br>(22) International Filing Date: 3 June 1987 (03.06.87)<br><br>(31) Priority Application Number: 871,102<br>(32) Priority Date: 4 June 1986 (04.06.86)<br>(33) Priority Country: US<br><br>(71) Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US).<br>(72) Inventors: BARGMANN, Cornelia, I. ; 56 Fairmont Street, Arlington, MA 02174 (US). WEINBERG, Robert, A. ; 25 Copley Street, Brookline, MA 02146 (US).<br>(74) Agent: GRANAHAN, Patricia; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US). | (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).<br><br>Published<br><i>With international search report.</i><br><br>(88) Date of publication of the international search report: 11 February 1988 (11.02.88) |
|--|--|

## (54) Title: DETECTION OF POINT MUTATIONS IN NEUGENES

## (57) Abstract

Oligonucleotide probes reactive with regions of *neu* oncogenes of mammalian origin in which the mutation causing activation of such oncogenes is contained are described, as are methods for their use in detecting the presence of *neu* oncogenes in tumor cells. Antibodies specific for gene products encoded by *neu* oncogenes are also described.



***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|                                 |   |                             |
|---------------------------------|---|-----------------------------|
| AT Austria                      | FR France                                   | ML Mali                     |
| AU Australia                    | GA Gabon                                    | MR Mauritania               |
| BB Barbados                     | GB United Kingdom                           | MW Malawi                   |
| BE Belgium                      | HU Hungary                                  | NL Netherlands              |
| BG Bulgaria                     | IT Italy                                    | NO Norway                   |
| BJ Benin                        | JP Japan                                    | RO Romania                  |
| BR Brazil                       | KP Democratic People's Republic<br>of Korea | SD Sudan                    |
| CF Central African Republic     | KR Republic of Korea                        | SE Sweden                   |
| CG Congo                        | LI Liechtenstein                            | SN Senegal                  |
| CH Switzerland                  | LK Sri Lanka                                | SU Soviet Union             |
| CM Cameroon                     | LU Luxembourg                               | TD Chad                     |
| DE Germany, Federal Republic of | MC Monaco                                   | TG Togo                     |
| DK Denmark                      | MG Madagascar                               | US United States of America |
| FI Finland                      |   |                             |

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 87/01282

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>4</sup>: C 12 Q 1/68; C 12 N 15/00; G 01 N 33/574

## II. FIELDS SEARCHED

## Minimum Documentation Searched ?

| Classification System | Classification Symbols     |
|-----------------------|----------------------------|
| IPC <sup>4</sup>      | C 12 Q<br>C 12 N<br>G 01 N |

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched \*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT\*

| Category * | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>  | Relevant to Claim No. <sup>13</sup> |
|------------|---|-------------------------------------|
| A, P       | Chemical Abstracts, volume 105, no. 7, 18 August 1986, (Columbus, Ohio, US), C.I. Bargmann et al.: "Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185", see page 162, abstract 55561a, & Cell (Cambridge, Mass.) 1986, 45(5), 649-57<br>-- | 1-10                                |
| A          | Nature, volume 312, 6 December 1984, A.L. Schechter et al.: "The Neu oncogene: an Erb-B-related gene encoding a 185,000-M <sub>r</sub> tumour antigen", pages 513-516<br>see the whole article<br>--  | 1-6                                 |
| A          | Proceedings of the National Academy of Sciences USA, volume 83, January 1986, M.-C. Hung et al.: "Molecular cloning of the Neu gene: Absence of gross structural alteration in oncogenic alleles", pages 261-264<br>see the whole article<br>cited in the application                                       | 1-10                                |

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"G" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

25th August 1987

Date of Mailing of this International Search Report

11 JAN 1988

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. VAN MOL

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category | Citation of Document, with indication, where appropriate, of the relevant passages   | Relevant to Claim No |
|----------|--|----------------------|
| A        | Nature, volume 319, 16 January 1986,<br>C.I. Bargmann et al.: "The Neu<br>oncogene encodes an epidermal growth<br>factor receptor-related protein",<br>pages 226-229<br>see the whole article<br>cited in the application                | 1-6                  |
| A        | Nature, volume 319, 16 January 1986,<br>T. Yamamoto et al.: "Similarity of<br>protein encoded by the human c-erb-B-2<br>gene to epidermal growth factor<br>receptor", pages 230-234<br>see the whole article<br>cited in the application | 1-6                  |
| A        | EP, A, 0108564 (THE REGENTS OF THE<br>UNIVERSITY OF CALIFORNIA) 16 May 1984<br>see page 1, line 1 - page 8, line 6   | 1-10                 |
| A        | Science, volume 225, 14 September 1984,<br>I. Guerrero et al.: "Activation of a<br>c-K-ras oncogene by somatic mutation<br>in mouse lymphomas induced by gamma<br>radiation", pages 1159-1162<br>see the whole article                   | 1-10                 |
|          |  |                      |

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V.  OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1.  Claim numbers ..... because they relate to subject matter not required to be searched by this Authority, namely:

2.  Claim numbers ....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.  Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this International application as follows:

- claims 1-10
- claims 11-14

(See Form PCT/ISA/206 d.d. 18th September 1987)

1.  As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.

2.  As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3.  No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1-10.

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

US 8701282  
SA 17498

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 09/12/87. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent document cited in search report | Publication date | Patent family member(s) |          | Publication date |
|--|------------------|-------------------------|----------|------------------|
| EP-A- 0108564                          | 16-05-84         | AU-A-                   | 2065083  | 10-05-84         |
|  |                  | JP-A-                   | 59113898 | 30-06-84         |
|  |                  | AU-B-                   | 559912   | 26-03-87         |
|  |                  | US-A-                   | 4699877  | 13-10-87         |